Nuvation Bio vs Zymeworks
NUVB and ZYME side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How NUVB and ZYME compare
Zymeworks is the larger company, worth 1.4 times as much as Nuvation Bio ($2.1B against $1.5B).
Nuvation Bio grew revenue faster over the last twelve months (654% versus 97.8% for Zymeworks).
Zymeworks keeps more of each dollar of sales as profit, with a net margin of 16.3% compared with −67.4% at Nuvation Bio.
Zymeworks scores higher on the StockData Score (10 against 4 for Nuvation Bio), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | NUVB | ZYME |
|---|---|---|
| Size and price | ||
| Market cap | $1.5B | $2.1B |
| Share price | $4.29 | $29.07 |
| Change, 1 year | −7.5% | 61.1% |
| Change, 5 years | −52.6% | 46.7% |
| Beta (5Y) | 1.46 | 0.84 |
| Employees | 298 | 264 |
| StockData Score | ||
| Total score | 4 | 10 (better) |
| Valuation score | 0 | 0 |
| Growth score | 1 | 1 |
| Performance score | 1 | 4 (better) |
| Health score | 2 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | – | 55.9× |
| P/S | 7.5× (better) | 7.8× |
| P/B | 6.6× (better) | 8.0× |
| EV/EBITDA | – | 44.4× |
| FCF yield | – | −5.5% |
| Fair value | $2.00 | $12.06 |
| Margin of safety | −115% (better) | −141% |
| Growth | ||
| Revenue growth (TTM) | 654% (better) | 97.8% |
| Revenue growth, 5Y average | – | 22.2% |
| Profitability | ||
| Operating margin | −61.2% | 16.6% (better) |
| Net margin | −67.4% | 16.3% (better) |
| FCF margin | – | −42.4% |
| Return on equity | −49.1% | 15.0% (better) |
| Return on invested capital | – | 21.4% |
| Financial health | ||
| Debt / equity | 0.03 (better) | 0.00 |
| Interest coverage | −5.9× | – |
| Current ratio | 7.45 (better) | 3.30 |
| Altman Z-score | 0.17 | 0.87 (better) |
| Piotroski F-score | 4 | 6 (better) |
| Dividends and buybacks | ||
| Buyback yield | – | 8.0% |
| Shareholder yield | 0.00% | 8.0% (better) |
| Ownership | ||
| Held by institutions | 66.5% | 98.1% |
| Held by insiders | 26.4% | 58.9% |
| Insider net buying, 12 months | −$4.5M (better) | −$5.0M |
| Superinvestors holding | 2 | – |
| Short interest, % of float | 24.0% | 20.3% |
Go deeper
- NUVB stock overview
- NUVB income statement
- NUVB valuation and score
- ZYME stock overview
- ZYME income statement
- ZYME valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.